DSIP

5mg Vial

10mg Vial

15mg Vial

2 September 2026Updated 20 October 2026

DSIP

Overview Research10 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for DSIP.

Create free account Member login

Full range of benefits for DSIP

May promote initiation of slow-wave (deep) sleep

May reduce sleep latency and improve sleep continuity

May normalize disrupted sleep architecture (REM/SWS balance)

May modulate hypothalamic–pituitary–adrenal (HPA) axis activity

May reduce stress-related arousal and anxiety-like responses

May influence growth hormone secretion patterns during sleep

May affect thermoregulation and core body temperature rhythms

Evidence for neuromodulatory and neuroprotective effects in animals

May support circadian rhythm entrainment and sleep timing

May modulate nociception and pain responses in preclinical studies

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 17 known interactions

Synergistic(4)Compatible(3)Monitor(5)Avoid(5)

Use with professional oversight

Benzodiazepines and Z-drugs (e.g., diazepam, zolpidem)

Monitor for excessive sedation, cognitive impairment and respiratory depression and consider dose reduction because combined CNS depressant effects may be additive.

Opioid analgesics

Closely monitor respiratory status and sedation level as DSIP may increase overall sedative burden and require opioid dose reassessment.

Antihypertensives (ACE inhibitors, beta-blockers, calcium channel blockers)

Monitor blood pressure and orthostatic symptoms because DSIP's influence on stress pathways can modestly affect autonomic tone and blood pressure control.

Systemic corticosteroids

Monitor clinical response and HPA-axis related parameters since DSIP can modulate stress responses and may alter glucocorticoid effects or requirements.

Anticoagulants (warfarin, DOACs)

Monitor coagulation parameters (e.g., INR) when initiating or stopping DSIP as indirect effects on physiology could necessitate closer anticoagulant monitoring.

All interaction categories

Synergistic (4)

Melatonin: Exogenous melatonin complements DSIP's sleep-promoting effects by synchronizing circadian rhythm and can enhance sleep initiation and consolidation when used together.
Oral magnesium (e.g., magnesium glycinate): Magnesium supplementation supports relaxation and sleep through modulation of NMDA/GABA pathways and may additively improve sleep quality alongside DSIP.
Trazodone (low-dose): Low-dose trazodone's sedative and sleep-maintaining properties can potentiate DSIP's therapeutic effect on sleep, particularly for sleep maintenance problems.
L-theanine: L-theanine promotes relaxation and reduced sleep latency via modulation of alpha brain waves and may synergize with DSIP to improve subjective sleep quality.

Compatible (3)

Levothyroxine: No known direct pharmacodynamic or pharmacokinetic interaction with DSIP; standard thyroid replacement monitoring remains appropriate.
Atorvastatin (statins): Statin therapy has no established interaction with DSIP and can be co-administered without special adjustment related to the peptide.
Ibuprofen (NSAIDs): Common short-term use of NSAIDs has no known interaction with DSIP and does not generally require adjustment for co-administration.

Monitor (5)

Benzodiazepines and Z-drugs (e.g., diazepam, zolpidem): Monitor for excessive sedation, cognitive impairment and respiratory depression and consider dose reduction because combined CNS depressant effects may be additive.
Opioid analgesics: Closely monitor respiratory status and sedation level as DSIP may increase overall sedative burden and require opioid dose reassessment.
Antihypertensives (ACE inhibitors, beta-blockers, calcium channel blockers): Monitor blood pressure and orthostatic symptoms because DSIP's influence on stress pathways can modestly affect autonomic tone and blood pressure control.
Systemic corticosteroids: Monitor clinical response and HPA-axis related parameters since DSIP can modulate stress responses and may alter glucocorticoid effects or requirements.
Anticoagulants (warfarin, DOACs): Monitor coagulation parameters (e.g., INR) when initiating or stopping DSIP as indirect effects on physiology could necessitate closer anticoagulant monitoring.

Avoid (5)

Opioids: Exercise caution due to the risk of additive sedation and respiratory depression when combining opioids with DSIP.
Gabapentinoids (gabapentin, pregabalin): Use caution because combined central nervous system depression (sedation, dizziness) may be additive and impair function.
Alcohol and other recreational CNS depressants: Avoid or minimize co-use because alcohol can substantially increase sedation, cognitive impairment and respiratory depression risk with DSIP.
Antipsychotics with sedative properties (e.g., quetiapine): Caution is warranted due to overlapping sedative and metabolic effects that can increase risk of daytime sedation and orthostasis.
SSRIs/SNRIs: Evaluate carefully for changes in sleep architecture and daytime somnolence when combining with DSIP, and adjust therapy if clinically indicated.